SpliceBio Secures $135 Million Series B Funding to Combat Genetic Disorders
Deal News | Jun 11, 2025 | EQT
EQT Life Sciences, in partnership with Sanofi Ventures, has co-led a $135 million Series B funding round for SpliceBio, a Spanish biotech company focused on genetic medicines. The financing will primarily advance the clinical trial development of SpliceBio’s lead gene therapy candidate, SB-007, intended for Stargardt disease, a genetic condition leading to vision loss. The round also included participation from Roche Venture Fund and existing investors such as New Enterprise Associates, among others. SpliceBio’s innovative platform uses Protein Splicing technology to address the challenges of delivering large genes, potentially setting the stage for treating a range of genetic disorders beyond ophthalmology and neurology. The investment marks a significant milestone for SpliceBio in its mission to pioneer gene therapies for currently untreatable diseases.
Sectors
- Biotechnology
- Healthcare
- Venture Capital
Geography
- Spain – SpliceBio, the target company receiving funding, is based in Spain.
- Europe – EQT Life Sciences, a European investment firm, is a key player in the financing round.
- United States – Sanofi Ventures and New Enterprise Associates, major participants in the funding, are based in the United States.
Industry
- Biotechnology – The article is focused on a biotechnology company, SpliceBio, which is developing therapies for genetic diseases.
- Healthcare – Healthcare is relevant as the article discusses funding for treatments targeting ophthalmology and neurology diseases.
- Venture Capital – EQT Life Sciences and other investors' involvement in funding positions this article within the Venture Capital sector.
Financials
- USD 135 Million – The total amount raised in the Series B financing round for SpliceBio.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| SpliceBio | Target Company | Company | A Spanish biotech company developing therapies for genetic diseases using Protein Splicing technology. |
| EQT Life Sciences | Leading Investor | Company | A venture capital firm focused on life sciences and healthcare. |
| Sanofi Ventures | Leading Investor | Company | A corporate venture capital fund that invests in early-to-mid-stage innovative life science companies. |
| Roche Venture Fund | Investor | Company | Part of the Roche Group investing in life sciences companies. |
| New Enterprise Associates | Existing Investor | Company | A global venture capital firm supporting innovative biotechnology firms. |
| UCB Ventures | Existing Investor | Company | The venture arm of UCB, focusing on therapies addressing severe diseases. |
| Ysios Capital | Existing Investor | Company | A Spanish venture capital firm focusing on life sciences. |
| Gilde Healthcare | Existing Investor | Company | A Dutch investment firm specializing in healthcare and biotechnology. |
| Novartis Venture Fund | Existing Investor | Company | An investment arm of Novartis focusing on biotechnology and life sciences. |
| Asabys Partners | Existing Investor | Company | A Spanish venture capital firm investing in life sciences. |
| Miquel Vila-Perell | Chief Executive Officer | Person | CEO and Co-Founder of SpliceBio. |
| Daniela Begolo | Managing Director | Person | Managing Director at EQT Life Sciences, joining the SpliceBio Board of Directors. |